SynthesisFrontiers in medicine2025
Impact of glucocorticoid administration on therapeutic outcomes of immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Efficacy and Safety of Dupilumab in Immune Checkpoint Inhibitor Induced Bullous Pemphigoid: A Spanish Multicentric Case Series.Acta dermato-venereologica · 2026Observational
- Independent Risk Factors and Nomogram-Based Prediction of Pulmonary Fungal Infection in Lung Cancer Inpatients: A Single-Center Retrospective Study.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality. Immune checkpoint inhibitors (ICIs) have improved outcomes in advanced NSCLC, yet concurrent glucocorticoid use raises concerns due to immunosuppressive effects. Evidence regarding the prognostic impact of glucocorticoids in this setting remains inconsistent. This study aimed to systematically evaluate the association between glucocorticoid use and survival outcomes in NSCLC patients receiving ICIs, with particular attention to timing of administration. Methods: A systematic search of PubMed, Embase, Web of Science, and the Cochrane Library was conducted up to December 18, 2024, with no language restrictions. Eligible studies enrolled adult NSCLC patients treated with ICIs, stratified by glucocorticoid exposure, and reported overall survival (OS), progression-free survival (PFS), or objective response rate (ORR). Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using fixed- or random-effects models depending on heterogeneity. Study quality was appraised with the Newcastle-Ottawa Scale, and evidence certainty was evaluated using GRADE. Subgroup analyses were conducted to assess the impact of glucocorticoid timing (pre-ICI, at initiation, and post-ICI) on survival outcomes. Results: Fifteen studies involving 5,950 patients were included. Glucocorticoid use was significantly associated with inferior outcomes. The pooled HR for PFS was 1.44 (95% CI, 1.15-1.73; Conclusion: In NSCLC patients receiving ICI therapy, glucocorticoid use might be associated with significantly poorer progression-free and overall survival, particularly when administered after the initiation of ICIs. Further research is warranted to clarify the timing and dosing parameters that could minimize potential negative effects on ICI efficacy. Systematic review registration: PROSPERO, identifier CRD420251156730, available from https://www.crd.york.ac.uk/PROSPERO/view/CRD420251156730.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.